{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,9]],"date-time":"2024-08-09T08:28:33Z","timestamp":1723192113420},"reference-count":22,"publisher":"Japanese Society of Internal Medicine","issue":"16","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2022,8,15]]},"DOI":"10.2169\/internalmedicine.9055-21","type":"journal-article","created":{"date-parts":[[2022,1,31]],"date-time":"2022-01-31T22:08:26Z","timestamp":1643666906000},"page":"2509-2515","source":"Crossref","is-referenced-by-count":3,"title":["Resection of Gastric Cancer Remitted Anti-signal Recognition Particle Myopathy"],"prefix":"10.2169","volume":"61","author":[{"given":"Yoshihide","family":"Sehara","sequence":"first","affiliation":[{"name":"Department of Neurology, Haga Red Cross Hospital, Japan"},{"name":"Division of Genetic Therapeutics, Center for Molecular Medicine, Jichi Medical University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyoichiro","family":"Tsuchiya","sequence":"additional","affiliation":[{"name":"Department of Diabetes and Endocrinology, University of Yamanashi Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ichizo","family":"Nishino","sequence":"additional","affiliation":[{"name":"Department of Neuromuscular Research, National Institute of Neuroscience, National Center of Neurology and Psychiatry (NCNP), Japan"},{"name":"Department of Genome Medicine Development, Medical Genome Center, National Center of Neurology and Psychiatry (NCNP), Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirotake","family":"Sato","sequence":"additional","affiliation":[{"name":"Department of Surgery, Haga Red Cross Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshihito","family":"Ando","sequence":"additional","affiliation":[{"name":"Department of Neurology, Haga Red Cross Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Dalakas MC. Inflammatory muscle diseases. N Engl J Med 372: 1734-1747, 2015.","DOI":"10.1056\/NEJMra1402225"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Mariampillai K, Granger B, Amelin D, et al. Development of a new classification system for idiopathic inflammatory myopathies based on clinical manifestations and myositis-specific autoantibodies. JAMA Neurol 75: 1528-1537, 2018.","DOI":"10.1001\/jamaneurol.2018.2598"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Tanboon J, Nishino I. Classification of idiopathic inflammatory myopathies: pathology perspectives. Curr Opin Neurol 32: 704-714, 2019.","DOI":"10.1097\/WCO.0000000000000740"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Tanboon J, Uruha A, Stenzel W, Nishino I. Where are we moving in the classification of idiopathic inflammatory myopathies? Curr Opin Neurol 33: 590-603, 2020.","DOI":"10.1097\/WCO.0000000000000855"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Allenbach Y, Benveniste O, Stenzel W, Boyer O. Immune-mediated necrotizing myopathy: clinical features and pathogenesis. Nat Rev Rheumatol 16: 689-701, 2020.","DOI":"10.1038\/s41584-020-00515-9"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Watanabe Y, Uruha A, Suzuki S, et al. Clinical features and prognosis in anti-SRP and anti-HMGCR necrotising myopathy. J Neurol Neurosurg Psychiatry 87: 1038-1044, 2016.","DOI":"10.1136\/jnnp-2016-313166"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Allenbach Y, Keraen J, Bouvier AM, et al. High risk of cancer in autoimmune necrotizing myopathies: usefulness of myositis specific antibody. Brain 139: 2131-2135, 2016.","DOI":"10.1093\/brain\/aww054"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Anquetil C, Boyer O, Wesner N, Benveniste O, Allenbach Y. Myositis-specific autoantibodies, a cornerstone in immune-mediated necrotizing myopathy. Autoimmun Rev 18: 223-230, 2019.","DOI":"10.1016\/j.autrev.2018.09.008"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Allenbach Y, Mammen AL, Benveniste O, Stenzel W. 224th ENMC International Workshop: clinico-sero-pathological classification of immune-mediated necrotizing myopathies Zandvoort, The Netherlands, 14-16 October 2016. Neuromuscul Disord 28: 87-99, 2018.","DOI":"10.1016\/j.nmd.2017.09.016"},{"key":"10","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1212\/WNL.0000000000003568","volume":"88","author":"A Uruha","year":"2017","unstructured":"10. Uruha A, Nishikawa A, Tsuburaya RS, et al. Sarcoplasmic MxA expression: a valuable marker of dermatomyositis. Neurology 88: 493-500, 2017.","journal-title":"Neurology","ISSN":"http:\/\/id.crossref.org\/issn\/0028-3878","issn-type":"print"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Uruha A, Allenbach Y, Charuel JL, et al. Diagnostic potential of sarcoplasmic myxovirus resistance protein A expression in subsets of dermatomyositis. Neuropathol Appl Neurobiol 45: 513-522, 2019.","DOI":"10.1111\/nan.12519"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Hoogendijk JE, Amato AA, Lecky BR, et al. 119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10-12 October 2003, Naarden, The Netherlands. Neuromuscul Disord 14: 337-345, 2004.","DOI":"10.1016\/j.nmd.2004.02.006"},{"key":"13","doi-asserted-by":"publisher","unstructured":"13. Allenbach Y, Arouche-Delaperche L, Preusse C, et al. Necrosis in anti-SRP<sup>+<\/sup> and anti-HMGCR<sup>+<\/sup> myopathies: role of autoantibodies and complement. Neurology 90: e507-e517, 2018.","DOI":"10.1212\/WNL.0000000000004923"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Bergua C, Chiavelli H, Allenbach Y, et al. <i>In vivo<\/i> pathogenicity of IgG from patients with anti-SRP or anti-HMGCR autoantibodies in immune-mediated necrotising myopathy. Ann Rheum Dis 78: 131-139, 2019.","DOI":"10.1136\/annrheumdis-2018-213518"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Ohnuki Y, Suzuki S, Shiina T, et al. HLA-DRB1 alleles in immune-mediated necrotizing myopathy. Neurology 87: 1954-1955, 2016.","DOI":"10.1212\/WNL.0000000000003160"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Rothwell S, Chinoy H, Lamb JA, et al.; Myositis Genetics Consortium (MYOGEN). Focused HLA analysis in Caucasians with myositis identifies significant associations with autoantibody subgroups. Ann Rheum Dis 78: 996-1002, 2019.","DOI":"10.1136\/annrheumdis-2019-215046"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Mammen AL, Chung T, Christopher-Stine L, et al. Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathy. Arthritis Rheum 63: 713-721, 2011.","DOI":"10.1002\/art.30156"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Ge Y, Lu X, Peng Q, Shu X, Wang G. Clinical characteristics of anti-3-hydroxy-3-methylglutaryl coenzyme A reductase antibodies in Chinese patients with idiopathic inflammatory myopathies. PLoS One 10: e0141616, 2015.","DOI":"10.1371\/journal.pone.0141616"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Kadoya M, Hida A, Hashimoto Maeda M, et al. Cancer association as a risk factor for anti-HMGCR antibody-positive myopathy. Neurol Neuroimmunol Neuroinflamm 3: e290, 2016.","DOI":"10.1212\/NXI.0000000000000290"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Yamaguchi T, Matsunaga A, Ikawa M, Shirafuji N, Nishino I, Hamano T. [A case of anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase antibody-positive paraneoplastic necrotizing myopathy associated with advanced gastric cancer that responded to intravenous immunoglobulin therapy]. Rinsho Shinkeigaku (Clin Neurol) 57: 118-123, 2017 (in Japanese).","DOI":"10.5692\/clinicalneurol.cn-000982"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Budhram A, Sechi E, Flanagan EP, et al. Clinical spectrum of high-titre GAD65 antibodies. J Neurol Neurosurg Psychiatry 92: 645-654, 2021.","DOI":"10.1136\/jnnp-2020-325275"},{"key":"22","doi-asserted-by":"publisher","unstructured":"22. Dimitriadou MM, Alexopoulos H, Akrivou S, Gola E, Dalakas MC. Anti-neuronal antibodies within the IVIg preparations: importance in clinical practice. Neurotherapeutics 17: 235-242, 2020.","DOI":"10.1007\/s13311-019-00796-3"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/61\/16\/61_9055-21\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T05:18:58Z","timestamp":1715231938000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/61\/16\/61_9055-21\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,15]]},"references-count":22,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.9055-21","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,15]]},"article-number":"9055-21"}}